Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Baliakas, Panagiotis ; Agathangelidis, Andreas ; Hadzidimitriou, Anastasia ; Sutton, Lesley-Ann ; Minga, Eva ; Tsanousa, Athina ; Scarfò, Lydia ; Davis, Zadie ; Yan, Xiao-Jie and Shanafelt, Tait , et al. (2015) In Blood 125(5). p.856-859
Abstract
An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between... (More)
An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
125
issue
5
pages
856 - 859
publisher
American Society of Hematology
external identifiers
  • pmid:25634617
  • wos:000350814900020
  • scopus:84921856679
  • pmid:25634617
ISSN
1528-0020
DOI
10.1182/blood-2014-09-600874
language
English
LU publication?
yes
id
afc63736-e60e-4c2c-a795-d984838b7cc9 (old id 5038984)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25634617?dopt=Abstract
date added to LUP
2016-04-01 10:09:08
date last changed
2022-04-04 02:51:52
@article{afc63736-e60e-4c2c-a795-d984838b7cc9,
  abstract     = {{An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.}},
  author       = {{Baliakas, Panagiotis and Agathangelidis, Andreas and Hadzidimitriou, Anastasia and Sutton, Lesley-Ann and Minga, Eva and Tsanousa, Athina and Scarfò, Lydia and Davis, Zadie and Yan, Xiao-Jie and Shanafelt, Tait and Plevova, Karla and Sandberg, Yorick and Vojdeman, Fie Juhl and Boudjogra, Myriam and Tzenou, Tatiana and Chatzouli, Maria and Chu, Charles C and Veronese, Silvio and Gardiner, Anne and Mansouri, Larry and Smedby, Karin E and Pedersen, Lone Bredo and Moreno, Denis and Van Lom, Kirsten and Giudicelli, Véronique and Francova, Hana Skuhrova and Nguyen-Khac, Florence and Panagiotidis, Panagiotis and Juliusson, Gunnar and Angelis, Lefteris and Anagnostopoulos, Achilles and Lefranc, Marie-Paule and Facco, Monica and Trentin, Livio and Catherwood, Mark and Montillo, Marco and Geisler, Christian H and Langerak, Anton W and Pospisilova, Sarka and Chiorazzi, Nicholas and Oscier, David and Jelinek, Diane F and Darzentas, Nikos and Belessi, Chrysoula and Davi, Frederic and Ghia, Paolo and Rosenquist, Richard and Stamatopoulos, Kostas}},
  issn         = {{1528-0020}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{856--859}},
  publisher    = {{American Society of Hematology}},
  series       = {{Blood}},
  title        = {{Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.}},
  url          = {{http://dx.doi.org/10.1182/blood-2014-09-600874}},
  doi          = {{10.1182/blood-2014-09-600874}},
  volume       = {{125}},
  year         = {{2015}},
}